{"id":745706,"date":"2018-06-13T05:45:00","date_gmt":"2018-06-13T05:45:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-sbla-for-gardasil9-in-women-and-men-ages-27-to-45-for-the-prevention-of-certain-hpv-related-cancers-and\/"},"modified":"2025-11-07T01:27:14","modified_gmt":"2025-11-07T06:27:14","slug":"fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-sbla-for-gardasil9-in-women-and-men-ages-27-to-45-for-the-prevention-of-certain-hpv-related-cancers-and","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-sbla-for-gardasil9-in-women-and-men-ages-27-to-45-for-the-prevention-of-certain-hpv-related-cancers-and\/","title":{"rendered":"FDA Grants Priority Review to Merck\u2019s Supplemental Biologics License Application (sBLA) for GARDASIL\u00ae9 in Women and Men Ages 27 to 45 for the Prevention of Certain HPV-Related Cancers and Diseases"},"content":{"rendered":"<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that the U.S. Food and Drug Administration (FDA) has<br \/>\n      accepted for review a new supplemental Biologics License Application<br \/>\n      (sBLA) for GARDASIL<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup>9 (Human Papillomavirus 9-valent<br \/>\n      Vaccine, Recombinant), the company\u2019s 9-valent HPV vaccine. The<br \/>\n      application is seeking approval for an expanded age indication for<br \/>\n      GARDASIL 9 for use in women and men ages 27 to 45 for the prevention of<br \/>\n      certain cancers and diseases caused by the nine human papillomavirus<br \/>\n      (HPV) types covered by the vaccine. The FDA has granted Priority Review<br \/>\n      to this sBLA and has set a Prescription Drug User Fee Act (PDUFA), or<br \/>\n      target action, date of Oct. 6, 2018.\n    <\/p>\n<p>\n      \u201cWomen and men ages 27 to 45 continue to be at risk for acquiring HPV,<br \/>\n      which can lead to cervical cancer and certain other HPV-related cancers<br \/>\n      and diseases,\u201d said Dr. Alain Luxembourg, director, clinical research,<br \/>\n      Merck Research Laboratories. \u201cWe look forward to working with the FDA on<br \/>\n      the review of this application for GARDASIL 9, which, if approved, would<br \/>\n      enable more people to have access to the vaccine.\u201d\n    <\/p>\n<p>\n      GARDASIL 9 is a vaccine indicated in the U.S. in females 9 through 26<br \/>\n      years of age for the prevention of cervical, vulvar, vaginal, and anal<br \/>\n      cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58;<br \/>\n      pre-cancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18,<br \/>\n      31, 33, 45, 52, and 58; and genital warts caused by HPV types 6 and 11.<br \/>\n      GARDASIL 9 is also indicated in males 9 through 26 years of age for the<br \/>\n      prevention of anal cancer caused by HPV types 16, 18, 31, 33, 45, 52,<br \/>\n      and 58; precancerous or dysplastic lesions caused by HPV types 6, 11,<br \/>\n      16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV types 6<br \/>\n      and 11.\n    <\/p>\n<p>\n      GARDASIL 9 is contraindicated in individuals with hypersensitivity,<br \/>\n      including severe allergic reactions to yeast, or after a previous dose<br \/>\n      of GARDASIL 9 or GARDASIL<sup>\u00ae<\/sup> [Human Papillomavirus Quadrivalent<br \/>\n      (Types 6, 11, 16, and 18) Vaccine, Recombinant].\n    <\/p>\n<p>\n      <b>About GARDASIL<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b>9 (Human Papillomavirus<br \/>\n      9-valent Vaccine, Recombinant)<\/b>\n    <\/p>\n<p>\n      GARDASIL 9 includes the greatest number of HPV types in any available<br \/>\n      HPV vaccine. After HPV types 16 and 18, the five additional HPV types in<br \/>\n      GARDASIL 9 are the most common cervical cancer-causing types worldwide.<br \/>\n      Seven HPV types in GARDASIL 9 (HPV 16, 18, 31, 33, 45, 52 and 58) cause<br \/>\n      approximately 90 percent of cervical cancer cases and approximately 80<br \/>\n      percent of high-grade cervical lesions (cervical precancers, defined as<br \/>\n      CIN 2, CIN 3 and AIS) worldwide. These seven HPV types also cause 90<br \/>\n      percent of HPV-related vulvar cancers, 85 percent of HPV-related vaginal<br \/>\n      cancers, and 90 percent of HPV-related anal cancers. HPV types 6 and 11<br \/>\n      cause approximately 90 percent of genital warts cases. In addition,<br \/>\n      approximately 50 percent of cases of low-grade cervical lesions (CIN 1)<br \/>\n      are caused by the nine HPV types included in the vaccine.\n    <\/p>\n<p>\n      GARDASIL 9 is approved for use in more than 70 countries.\n    <\/p>\n<p>\n      <b>Important information about GARDASIL 9<\/b>\n    <\/p>\n<p>\n      GARDASIL 9 does not eliminate the necessity for women to continue to<br \/>\n      undergo recommended cervical cancer screening. Recipients of GARDASIL 9<br \/>\n      should not discontinue anal cancer screening if it has been recommended<br \/>\n      by a health care professional.\n    <\/p>\n<p>\n      GARDASIL 9 has not been demonstrated to provide protection against<br \/>\n      diseases from vaccine HPV types to which a person has previously been<br \/>\n      exposed through sexual activity.\n    <\/p>\n<p>\n      GARDASIL 9 is not a treatment for external genital lesions; cervical,<br \/>\n      vulvar, vaginal, and anal cancers; or cervical intraepithelial neoplasia<br \/>\n      (CIN), vulvar intraepithelial neoplasia (VIN), vaginal intraepithelial<br \/>\n      neoplasia (VaIN), or anal intraepithelial neoplasia (AIN).\n    <\/p>\n<p>\n      Not all vulvar, vaginal, and anal cancers are caused by HPV, and<br \/>\n      GARDASIL 9 protects only against those vulvar, vaginal, and anal cancers<br \/>\n      caused by HPV 16, 18, 31, 33, 45, 52, and 58.\n    <\/p>\n<p>\n      Vaccination with GARDASIL 9 may not result in protection in all vaccine<br \/>\n      recipients.\n    <\/p>\n<p>\n      <b>Select Safety Information for GARDASIL 9<\/b>\n    <\/p>\n<p>\n      GARDASIL 9 is contraindicated in individuals with hypersensitivity,<br \/>\n      including severe allergic reactions to yeast, or after a previous dose<br \/>\n      of GARDASIL 9 or GARDASIL.\n    <\/p>\n<p>\n      Because vaccinees may develop syncope, sometimes resulting in falling<br \/>\n      with injury, observation for 15 minutes after administration is<br \/>\n      recommended. Syncope, sometimes associated with tonic-clonic movements<br \/>\n      and other seizure-like activity, has been reported following HPV<br \/>\n      vaccination. When syncope is associated with tonic-clonic movements, the<br \/>\n      activity is usually transient and typically responds to restoring<br \/>\n      cerebral perfusion.\n    <\/p>\n<p>\n      Safety and effectiveness of GARDASIL 9 have not been established in<br \/>\n      pregnant women.\n    <\/p>\n<p>\n      The most common (\u226510%) local and systemic adverse reactions in females<br \/>\n      were injection-site pain, swelling, erythema, and headache. The most<br \/>\n      common (\u226510%) local and systemic reactions in males were injection-site<br \/>\n      pain, swelling, and erythema.\n    <\/p>\n<p>\n      The duration of immunity of GARDASIL 9 has not been established.\n    <\/p>\n<p>\n      <b>Dosage and administration for GARDASIL 9<\/b>\n    <\/p>\n<p>\n      GARDASIL 9 should be administered intramuscularly in the deltoid region<br \/>\n      of the upper arm or in the higher anterolateral area of the thigh.\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        For individuals 9 through 14 years of age, GARDASIL 9 can be<br \/>\n        administered using a<br \/>2-dose or 3-dose schedule. For the 2-dose<br \/>\n        schedule, the second dose should be administered 6-12 months after the<br \/>\n        first dose. If the second dose is administered less than 5 months<br \/>\n        after the first dose, a third dose should be given at least 4 months<br \/>\n        after the second dose. For the 3-dose schedule, GARDASIL 9 should be<br \/>\n        administered at<br \/>0, 2 months, and 6 months.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        For individuals 15 through 26 years of age, GARDASIL 9 is administered<br \/>\n        using a<br \/>3-dose schedule at 0, 2 months, and 6 months.\n      <\/li>\n<\/ul>\n<p>\n      <b>About HPV and HPV-related cancers and diseases<\/b>\n    <\/p>\n<p>\n      In the United States, human papillomavirus (HPV) will infect most<br \/>\n      sexually active males and females in their lifetime. According to the<br \/>\n      CDC, there are approximately 14 million new genital HPV infections in<br \/>\n      the United States each year, half of which occur in people 15 through 24<br \/>\n      years of age. For most people, HPV clears on its own, but for others who<br \/>\n      don&#8217;t clear the virus it could lead to certain cancers and other<br \/>\n      diseases in males and females. There is no way to predict who will or<br \/>\n      won\u2019t clear the virus.\n    <\/p>\n<p>\n      HPV causes virtually all cervical cancer cases. Each day, about 36 women<br \/>\n      are diagnosed with cervical cancer in the United States &#8212; about 13,200<br \/>\n      women per year. HPV also causes approximately 70-75 percent of vaginal<br \/>\n      cancer cases and approximately 30 percent of vulvar cancer cases in<br \/>\n      females, and approximately 85-90 percent of anal cancers and 90 percent<br \/>\n      of genital warts in both females and males.\n    <\/p>\n<p>\n      Anal cancer and genital warts affect both men and women. According to<br \/>\n      the American Cancer Society, an estimated 2,960 men and 5,620 women in<br \/>\n      the United States will be diagnosed with anal cancer in 2018, and<br \/>\n      overall rates have been increasing. There is no routine screening<br \/>\n      recommended for the general population to reduce the risk of anal<br \/>\n      cancer. Approximately 355,000 cases of genital warts occur each year in<br \/>\n      the United States. Approximately 3 out of 4 people get them after having<br \/>\n      genital contact with someone who has genital warts.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world&#8217;s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer&#8217;s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Findex.html&amp;esheet=51821521&amp;newsitemid=20180613005477&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=1&amp;md5=0940a12596308d6d166fdfca0bb082cd\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a>\u00a0and<br \/>\n      connect with us on\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51821521&amp;newsitemid=20180613005477&amp;lan=en-US&amp;anchor=Twitter&amp;index=2&amp;md5=ad83689662cc54d745fe20bb90775c03\" rel=\"nofollow\">Twitter<\/a>,\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=51821521&amp;newsitemid=20180613005477&amp;lan=en-US&amp;anchor=Facebook&amp;index=3&amp;md5=9d776ddaca52ea719897da3b21ebe433\" rel=\"nofollow\">Facebook<\/a>,\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=51821521&amp;newsitemid=20180613005477&amp;lan=en-US&amp;anchor=Instagram&amp;index=4&amp;md5=4a7535d4b58e42c8ad896406f7560538\" rel=\"nofollow\">Instagram<\/a>,\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51821521&amp;newsitemid=20180613005477&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=e7cc80db9f8f9fbdab9382cf53e16264\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51821521&amp;newsitemid=20180613005477&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=fc5c6485e664062888b291a9d5607a8d\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2017 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fna01.safelinks.protection.outlook.com%2F%3Furl%3Dhttp%253A%252F%252Fwww.sec.gov%252F%26data%3D02%257C01%257CNicole.Osborne%2540zenogroup.com%257Ce9971a84dfcb47175caf08d58f7dd5ae%257Cb824bfb3918e43c2bb1cdcc1ba40a82b%257C0%257C0%257C636572692983391771%26sdata%3D27NUJyF6yMXcEUejyAoXazFDe5TPRPU4kf6voSib16o%253D%26reserved%3D0&amp;esheet=51821521&amp;newsitemid=20180613005477&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=1310e1969b672fa0395bfb8fcba214f7\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for GARDASIL<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b>9<br \/>\n      (Human Papillomavirus 9-valent Vaccine, Recombinant) at\u00a0<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fg%2Fgardasil_9%2Fgardasil_9_pi.pdf&amp;esheet=51821521&amp;newsitemid=20180613005477&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fg%2Fgardasil_9%2Fgardasil_9_pi.pdf&amp;index=8&amp;md5=a447d3f487431f420ba1ae73ac766969\" rel=\"nofollow\">http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/g\/gardasil_9\/gardasil_9_pi.pdf<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<p>\n      <b>The Patient Product Information for GARDASIL 9 is also available at\u00a0<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fg%2Fgardasil_9%2Fgardasil_9_ppi.pdf&amp;esheet=51821521&amp;newsitemid=20180613005477&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fg%2Fgardasil_9%2Fgardasil_9_ppi.pdf&amp;index=9&amp;md5=f867e9de83ef6cba4e133f0eaeffa513\" rel=\"nofollow\">http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/g\/gardasil_9\/gardasil_9_ppi.pdf<\/a>.\n    <\/p>\n<\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20180613005477r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><br \/>\n<span class=\"bwct31415\" \/><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Deb        Wambold, 267-305-0642<br \/>or<br \/>Investors:<br \/>Teri Loxam,        908-740-1986<br \/>or<br \/>Michael DeCarbo, 908-740-1807     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a new supplemental Biologics License Application (sBLA) for GARDASIL \u00ae 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), the company\u2019s 9-valent HPV vaccine. The application is seeking approval for an expanded age indication for GARDASIL 9 for use in women and men ages 27 to 45 for the prevention of certain cancers and diseases caused by the nine human papillomavirus (HPV) types covered by the vaccine. The FDA has granted Priority Review to this sBLA and has set a Prescription Drug User Fee Act (PDUFA), or target action, date of Oct. 6, 2018. \u201cWomen and men ages 27 to 45 continue to be at risk for acquiring HPV, which can lead to cervical cancer and certain other HPV-related cancers and diseases,\u201d said Dr. Alain Luxembourg, director, clinical research, Merck Research Laboratories. \u201cWe look forward to working with the FDA on<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,57],"class_list":["post-745706","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-vaccine-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FDA Grants Priority Review to Merck\u2019s Supplemental Biologics License Application (sBLA) for GARDASIL\u00ae9 in Women and Men Ages 27 to 45 for the Prevention of Certain HPV-Related Cancers and Diseases - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-sbla-for-gardasil9-in-women-and-men-ages-27-to-45-for-the-prevention-of-certain-hpv-related-cancers-and\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Grants Priority Review to Merck\u2019s Supplemental Biologics License Application (sBLA) for GARDASIL\u00ae9 in Women and Men Ages 27 to 45 for the Prevention of Certain HPV-Related Cancers and Diseases - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a new supplemental Biologics License Application (sBLA) for GARDASIL \u00ae 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), the company\u2019s 9-valent HPV vaccine. The application is seeking approval for an expanded age indication for GARDASIL 9 for use in women and men ages 27 to 45 for the prevention of certain cancers and diseases caused by the nine human papillomavirus (HPV) types covered by the vaccine. The FDA has granted Priority Review to this sBLA and has set a Prescription Drug User Fee Act (PDUFA), or target action, date of Oct. 6, 2018. \u201cWomen and men ages 27 to 45 continue to be at risk for acquiring HPV, which can lead to cervical cancer and certain other HPV-related cancers and diseases,\u201d said Dr. Alain Luxembourg, director, clinical research, Merck Research Laboratories. \u201cWe look forward to working with the FDA on\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-sbla-for-gardasil9-in-women-and-men-ages-27-to-45-for-the-prevention-of-certain-hpv-related-cancers-and\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:27:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-sbla-for-gardasil9-in-women-and-men-ages-27-to-45-for-the-prevention-of-certain-hpv-related-cancers-and\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-sbla-for-gardasil9-in-women-and-men-ages-27-to-45-for-the-prevention-of-certain-hpv-related-cancers-and\\\/\",\"name\":\"FDA Grants Priority Review to Merck\u2019s Supplemental Biologics License Application (sBLA) for GARDASIL\u00ae9 in Women and Men Ages 27 to 45 for the Prevention of Certain HPV-Related Cancers and Diseases - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2018-06-13T05:45:00+00:00\",\"dateModified\":\"2025-11-07T06:27:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-sbla-for-gardasil9-in-women-and-men-ages-27-to-45-for-the-prevention-of-certain-hpv-related-cancers-and\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-sbla-for-gardasil9-in-women-and-men-ages-27-to-45-for-the-prevention-of-certain-hpv-related-cancers-and\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-sbla-for-gardasil9-in-women-and-men-ages-27-to-45-for-the-prevention-of-certain-hpv-related-cancers-and\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Grants Priority Review to Merck\u2019s Supplemental Biologics License Application (sBLA) for GARDASIL\u00ae9 in Women and Men Ages 27 to 45 for the Prevention of Certain HPV-Related Cancers and Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA Grants Priority Review to Merck\u2019s Supplemental Biologics License Application (sBLA) for GARDASIL\u00ae9 in Women and Men Ages 27 to 45 for the Prevention of Certain HPV-Related Cancers and Diseases - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-sbla-for-gardasil9-in-women-and-men-ages-27-to-45-for-the-prevention-of-certain-hpv-related-cancers-and\/","og_locale":"en_US","og_type":"article","og_title":"FDA Grants Priority Review to Merck\u2019s Supplemental Biologics License Application (sBLA) for GARDASIL\u00ae9 in Women and Men Ages 27 to 45 for the Prevention of Certain HPV-Related Cancers and Diseases - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a new supplemental Biologics License Application (sBLA) for GARDASIL \u00ae 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), the company\u2019s 9-valent HPV vaccine. The application is seeking approval for an expanded age indication for GARDASIL 9 for use in women and men ages 27 to 45 for the prevention of certain cancers and diseases caused by the nine human papillomavirus (HPV) types covered by the vaccine. The FDA has granted Priority Review to this sBLA and has set a Prescription Drug User Fee Act (PDUFA), or target action, date of Oct. 6, 2018. \u201cWomen and men ages 27 to 45 continue to be at risk for acquiring HPV, which can lead to cervical cancer and certain other HPV-related cancers and diseases,\u201d said Dr. Alain Luxembourg, director, clinical research, Merck Research Laboratories. \u201cWe look forward to working with the FDA on","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-sbla-for-gardasil9-in-women-and-men-ages-27-to-45-for-the-prevention-of-certain-hpv-related-cancers-and\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:27:14+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-sbla-for-gardasil9-in-women-and-men-ages-27-to-45-for-the-prevention-of-certain-hpv-related-cancers-and\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-sbla-for-gardasil9-in-women-and-men-ages-27-to-45-for-the-prevention-of-certain-hpv-related-cancers-and\/","name":"FDA Grants Priority Review to Merck\u2019s Supplemental Biologics License Application (sBLA) for GARDASIL\u00ae9 in Women and Men Ages 27 to 45 for the Prevention of Certain HPV-Related Cancers and Diseases - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2018-06-13T05:45:00+00:00","dateModified":"2025-11-07T06:27:14+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-sbla-for-gardasil9-in-women-and-men-ages-27-to-45-for-the-prevention-of-certain-hpv-related-cancers-and\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-sbla-for-gardasil9-in-women-and-men-ages-27-to-45-for-the-prevention-of-certain-hpv-related-cancers-and\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-sbla-for-gardasil9-in-women-and-men-ages-27-to-45-for-the-prevention-of-certain-hpv-related-cancers-and\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"FDA Grants Priority Review to Merck\u2019s Supplemental Biologics License Application (sBLA) for GARDASIL\u00ae9 in Women and Men Ages 27 to 45 for the Prevention of Certain HPV-Related Cancers and Diseases"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"09b216ce-fd7a-4343-84eb-94c22b292ef4","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745706","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":2,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745706\/revisions"}],"predecessor-version":[{"id":3675050,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745706\/revisions\/3675050"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745706"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745706"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}